Topics include the expanding role of biomarkers and updates on potassium binding agents, SGLT2 inhibitors and ARNIs. There will be talks on
remote monitoring, pulmonary arterial hypertension (PAH), new evidence of the beneficial effects of percutaneous treatment of valvular heart disease and the marked improvements in outcome that are now being seen with LVADs and cardiac transplantation. We’ll discuss old and new indications for DOAC’s, take an extensive look at the treatment of ventricular arrhythmias and review the role of left atrial closure devices and percutaneous cardiac pumps. The last session includes talks on some of the more problematic areas of patient management including, mid range EF, adults with congenital lesions and finally an overview of new and emerging therapies. As you can see, the 20th